JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target from $52 to $46.